DSM is a global leader in biomedical materials science – experience that we are now using to create advanced sustained release drug products as implantable or injectable delivery forms. DSM offers two proprietary, highly versatile polymer technologies which serve as platforms for the development of long-acting formulations of bioactive ingredients. ​

Breakthrough in eye treatment

Approximately 1.3 billion people around the world suffer some form of vision impairment. About 80% is considered avoidable. A key success factor in any eye therapy is the application of the right dosage of medicine in the right place over time. Diseases of the retina (back of the eye) require delivery of medicine via frequent localized needle injections that cause significant discomfort and inconvenience.

DSM developed an innovative, sustained-release drug delivery solution to address this therapeutic need. Targeting retinal disorders such as age-related macular degeneration (AMD) and diabetic macular edema (DME), it has shown strong efficacy in preclinical models. A small, injectable, biodegradable polymer fiber is loaded with medicine and injected at a specific location in the eye. The medicine is then released over several months until the fiber degrades. The new treatment is designed to reduce the need for injections in the eye from almost monthly to less than once every four months. Additional fibers can subsequently be injected to ensure continuous therapy.

We have commercialized this solution through a strategic R&D collaboration and license agreement with Aerie Pharmaceuticals. In 2019, the first ever clinical trial of the AR-13503 Sustained Release (SR) Implant in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) began. “This agreement opens up many new opportunities as we continue to innovate with new drugs and technologies to potentially treat many diseases of the eye,” says Dr. Vicente Anido, Jr., Chairman and Chief Executive Officer at Aerie. “This is a platform on which we can build our innovative sustained-release strategies for many ophthalmic diseases, including glaucoma.”

Purpose-led

With DSM’s sustained-release delivery solution we are helping people to live healthier and more fulfilling lives. The greatest long-term benefit may be to older individuals who are at a higher risk of developing eye-related illnesses; according to the World Health Organization (WHO), of the 253 million people affected by blindness and vision impairment, 81% are aged fifty or older. Furthermore, by enabling more successful treatment solutions at a patient level, the solution can help ease the growing socio-economic impact of eye disease in rapidly aging populations, such as in Europe, North America and Japan.

Performance-driven

A key step forward in our objective has been commercializing our solution through a strategic collaboration and license agreement with Aerie Pharmaceuticals, a leading ophthalmic pharmaceutical company. The partnership is helping to bring DSM’s innovation to millions of patients around the world and will potentially enable better treatment for a wide range of ophthalmic conditions.

The strong value proposition of our solution gives us a competitive edge, which we can replicate in other fields of medicine where sustained-release drug delivery may be beneficial.

Bioresorbable Polymer Platform

Our bioresorbable PolyEsterAmides (PEAs) provide formulators the ability to develop sustained release systems of small molecule  drugs and biologics for systemic and site-specific parenteral drug delivery. Release duration can be regulated from days to, for many drugs, more than six months.

Non-resorbable Polymer Platform

Our biomedical polyurethanes enjoy a long successful clinical history and give formulators a proven, customizable platform from which to create delivery of medications for systemic drug delivery with duration of several days to multiple months.  DSM’s extensive polymer expertise allows customization of both the bulk and surface chemistries for targeted compositions based on the pharmaceutical attributes and hydrophilicity requirements.

Markets served by this technology

  • Cardiovascular

    DSM Biomedical materials and technologies support cardiovascular applications, including neurologic and peripheral vascular. Learn more.

  • Diabetes Management

    DSM Biomedical materials and technologies support diabetes management and CGM applications.

  • Ophthalmology

    DSM Biomedical materials and technologies support ophthalmic, ophthalmology and drug delivery applications. Learn more.

  • Women's Health

    DSM Biomedical materials and technologies support womens health, breast and gynecological applications. Learn more.

Aliphatic Thermoplastic​ Polyether Polyurethane ​product sheet​

Medical grade polymer with exceptional physical and biocompatibility properties​.

Bionate® PCU​ product sheet​

Recognized as an industry-leading medical grade polymer for long-term use in the body​.

CarboSil® TSPCU​ product sheet​

Ground-breaking copolymer that combines the benefits of silicone and polyurethane.

Polyesteramide technology sheet​

Read more

  • Our products

    DSM portfolio of innovative biomedical materials and process manufacturing technologies: Biomedical Polyethylenes, Biomedical polyurethanes, Collagen Technology, Device Development, and Extracellular Matrix (ECM) Technology. Learn more.

  • The markets we serve

    DSM Biomedical offers the broadest portfolio of biomedical materials and manufacturing across market applications, including orthopedics, ophthalmology, neurology, cardiology, diabetes, wound, and continence care.

Want to get in touch?

We'd love to hear from you!

This site uses cookies to store information on your computer.

Learn more